Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I CHR-2845 dose-escalation study in refractory hematologic and lymphoid malignancies
NL-OMON33977Phase 1Active, not recruiting
- Sponsor
- Chroma Therapeutics
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tefinostat in hematopoietic malignancies, lymphoma, Acute Leukaemia and 7 more, sponsored by Chroma Therapeutics. Primary endpoints: Maximum acceptable dose, Maximum tolerated dose and 1 more. Started Mar 2009; status: active, not recruiting.
02
Drugs
tefinostat
03
Conditions
hematopoietic malignancieslymphomaAcute Leukaemiamyelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON33977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33977.